Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
| Last: | $3.1974 |
|---|---|
| Change Percent: | 6.4% |
| Open: | $2.99 |
| Close: | $3.005 |
| High: | $3.3 |
| Low: | $2.95 |
| Volume: | 11,255,436 |
| Last Trade Date Time: | 03/09/2026 12:45:18 pm |
| Market Cap: | $404,127,741 |
|---|---|
| Float: | 76,708,429 |
| Insiders Ownership: | 1.82% |
| Institutions: | 41 |
| Short Percent: | N/A |
| Industry: | Biotechnology & Life Sciences |
| Sector: | Healthcare |
| Website: | https://www.aclaristx.com |
| Country: | US |
| City: | Wayne |
Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI FAQ is based on asking OpenAI questions about Aclaris Therapeutics Inc. (NASDAQ: ACRS).
Link your X account with Market Wire News to automatically tweet trending stocks news and your portfolio stocks news.
Get instant news alerts to your mobile device as soon as the news hits the wire. Simply add a stock symbol to your portfolio and our service will alert you anytime there is news.
